Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leslie Amass

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Orphanet Journal of Rare Diseases|December 19, 2018
Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathyLeslie Amass, Huihua Li, Balarama K Gundapaneni, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 6, 2016
Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathyMárcia Waddington Cruz, Leslie Amass, Denis Keohane, et al.
Neurology and Therapy|May 23, 2021
Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)Márcia Waddington-Cruz, Jonas Wixner, Leslie Amass, et al.
Current Medical Research and Opinion|February 4, 2020
The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathyImtiaz A Samjoo, Elizabeth M Salvo, Diana Tran, et al.
Neurology and Therapy|April 2, 2020
Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid PolyneuropathyAlejandra González-Duarte, Isabel Conceição, Leslie Amass, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2006
Buprenorphine use: the international experienceMaria Patrizia Carrieri, Leslie Amass, Gregory M Lucas, et al.
Drug and Alcohol Dependence|March 22, 2002
Predictors of internalizing and externalizing problems among children of cocaine and opiate dependent parentsCatherine Stanger, Jody Kamon, Levent Dumenci, et al.
Cardiology and Therapy|July 9, 2025
Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOSJonas Wixner, Angela Dispenzieri, Leslie Amass, et al.
Cardiology and Therapy|July 29, 2025
Transthyretin Kinetic Stabilizers for ATTR Amyloidosis: A Narrative Review of Mechanisms and Therapeutic BenefitsEvan T Powers, Leslie Amass, Lori Baylor, et al.
Journal of Substance Abuse Treatment|July 30, 2010
Contingency management among homeless, out-of-treatment men who have sex with menCathy J Reback, James A Peck, Rhodri Dierst-Davies, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Orphanet Journal of Rare Diseases|December 19, 2018
Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathyLeslie Amass, Huihua Li, Balarama K Gundapaneni, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|August 6, 2016
Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathyMárcia Waddington Cruz, Leslie Amass, Denis Keohane, et al.
Neurology and Therapy|May 23, 2021
Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)Márcia Waddington-Cruz, Jonas Wixner, Leslie Amass, et al.
Current Medical Research and Opinion|February 4, 2020
The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathyImtiaz A Samjoo, Elizabeth M Salvo, Diana Tran, et al.
Neurology and Therapy|April 2, 2020
Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid PolyneuropathyAlejandra González-Duarte, Isabel Conceição, Leslie Amass, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2006
Buprenorphine use: the international experienceMaria Patrizia Carrieri, Leslie Amass, Gregory M Lucas, et al.
Drug and Alcohol Dependence|March 22, 2002
Predictors of internalizing and externalizing problems among children of cocaine and opiate dependent parentsCatherine Stanger, Jody Kamon, Levent Dumenci, et al.
Cardiology and Therapy|July 9, 2025
Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOSJonas Wixner, Angela Dispenzieri, Leslie Amass, et al.
Cardiology and Therapy|July 29, 2025
Transthyretin Kinetic Stabilizers for ATTR Amyloidosis: A Narrative Review of Mechanisms and Therapeutic BenefitsEvan T Powers, Leslie Amass, Lori Baylor, et al.
Journal of Substance Abuse Treatment|July 30, 2010
Contingency management among homeless, out-of-treatment men who have sex with menCathy J Reback, James A Peck, Rhodri Dierst-Davies, et al.
Pageof 5